Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 1:119:118055.
doi: 10.1016/j.bmc.2024.118055. Epub 2024 Dec 28.

Fine-tuning probes for fluorescence polarization binding assays of bivalent ligands against polo-like kinase 1 using full-length protein

Affiliations

Fine-tuning probes for fluorescence polarization binding assays of bivalent ligands against polo-like kinase 1 using full-length protein

Kohei Tsuji et al. Bioorg Med Chem. .

Abstract

Polo-like kinase 1 (Plk1) is an important cell cycle regulator that is a recognized target for development of anti-cancer therapeutics. Plk1 is composed of a catalytic kinase domain (KD), a flexible interdomain linker and a polo-box domain (PBD). Intramolecular protein-protein interactions (PPIs) between the PBD and KD result in "auto-inhibition" that is an essential component of proper Plk1 function. Recently, we developed high-affinity PBD-binding inhibitors using a bivalent approach. These ligands contain the low-nanomolar affinity Plk1 KD-binding inhibitors BI2536 or Wortmannin tethered to the PBD-binding peptide, PLH*SpT (H* represents a -(CH2)8Ph group on the histidine side chain π-nitrogen). Due to the extremely high affinity of these bivalent inhibitors, to avoid bottoming out in competitive binding assays, it was necessary to use PLH*SpT in the affinity probe. As reported herein, we have developed fluorescence polarization assays using a new fluorescent probe based on the Plk1 PBD-binding peptide, FDPPLHSpTA. We applied the assay to evaluate the affinities of bivalent inhibitors that possess a variety of PBD-binding peptides having much lower PBD-affinities than PLH*SpT. Tethering BI2536 in these bivalent inhibitors resulted in significant affinity enhancements as compared to the parent monovalent peptides.

Keywords: Bivalent inhibitor; Fluorescence Polarization (FP) assay; Phosphorylated threonine (pT); Polo-box domain (PBD); Polo-like kinase 1 (Plk1).

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1.
Fig. 1.
Structures of the reported Plk1 inhibitors BI2536, Lys(BI2536), PLH*SpT, PLHSpT, and bivalent inhibitors 18.,,
Fig. 2.
Fig. 2.
Plk1 PBD-binding assays. (a) ELISA assay using NeutrAvidin coated plate, biotin-labeled PMQSpTPLN, myc-tagged Plk1, anti-myc antibody and HRP-fused antibody,,; (b) FP assays using full-length Plk1 or isolated Plk1 PBD and FITC-labeled PLH*SpT, FITC-labeled FDPPLHSpTA, or 5CF-GPMQSpTPLNG. Ahx: 6-aminohexanoic Acid, HRP: horseradish peroxidase, FITC: fluorescein isothiocyanate, miniPEG: 8-amino-3,6-dioxaoctanoyl, 5CF: 5-carboxyfluorescein.
Fig. 3.
Fig. 3.
Structures of fluorescent probes used in FP assays.,
Fig. 4.
Fig. 4.
FP assays with different fluorescent probes. (a) Results from full-length Plk1assays using FITC-miniPEG-PLH*SpT as a probe. Binding curves and IC50 values for PLH*SpT, PLH*SpT + 1 μM BI2536, 1, 4, 5, and 8 have been previously reported. The X axis represents log (inhibitor concentration) and the Y axis represents % binding based on probe alone as 0% probe binding and probe with Plk1 as 100% probe binding. (b) Determination of KD values of each probe (10 nM). The X axis represents Plk1 concentration, and the Y axis represents FP signal intensity. The KD values for FITC-miniPEG-PLH*SpT (8.3 ± 0.80 nM) and FITC-miniPEG-FDPPLHSpTA (210 ± 16 nM) were determined from two independent experiments and shown as the average KD value ± SEM (nM).
Fig. 5.
Fig. 5.
Structures of pentapeptide-based bivalent ligands.
Fig. 6.
Fig. 6.
Structures of the tripeptide-based bivalent ligands.

Similar articles

Cited by

References

    1. Mayer BJ Protein-protein interactions in signaling cascades. Methods Mol Biol. 2006;332:79–99. 10.1385/1-59745-048-0:79 - DOI - PubMed
    1. Pawson T, Nash P Handbook of Cell Signaling (Second Edition), eds. Bradshaw RA and Dennis EA, Academic Press, San Diego, CA: 2010: pp. 399–411. 10.1016/B978-0-12-374145-5.00057-7 - DOI
    1. Roskoski R Jr. Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacol Res. 2016;103:26–48. 10.1016/j.phrs.2015.10.021 - DOI - PubMed
    1. Gower CM, Chang MEK, Maly DJ Bivalent inhibitors of protein kinases. Crit Rev Biochem Mol Biol. 2014;49:102–115. 10.3109/10409238.2013.875513 - DOI - PMC - PubMed
    1. Lavogina D, Enkvist E Uri A. Bisubstrate Inhibitors of Protein Kinases: from Principle to Practical Applications. ChemMedChem 2010;5:23–34. 10.1002/cmdc.200900252 - DOI - PubMed

MeSH terms

LinkOut - more resources